HC Wainwright Has Positive Outlook of Belite Bio Q3 Earnings

Key Points

• HC Wainwright has increased its Q3 2025 earnings forecast for Belite Bio to ($0.52) per share, up from ($0.53), maintaining a "Buy" rating and a $98.00 target price on the stock.
• Belite Bio's consensus estimate for the full-year 2025 earnings stands at ($1.17) per share, with additional quarterly estimates also provided for Q4 2025 and the next fiscal years.
• Despite a recent downgrade by Wall Street Zen from "hold" to "sell," Belite Bio still holds an average "Buy" rating among analysts with a target price of $96.00.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Free Report) - Equities research analysts at HC Wainwright boosted their Q3 2025 EPS estimates for Belite Bio in a research note issued on Monday, September 15th. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.52) for the quarter, up from their prior estimate of ($0.53). HC Wainwright currently has a "Buy" rating and a $98.00 price objective on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Belite Bio's Q4 2025 earnings at ($0.50) EPS, FY2025 earnings at ($1.97) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.47) EPS and FY2026 earnings at ($1.92) EPS.

Belite Bio (NASDAQ:BLTE - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.03). During the same period in the previous year, the firm posted ($0.31) EPS.

BLTE has been the topic of a number of other reports. Zacks Research raised shares of Belite Bio from a "strong sell" rating to a "hold" rating in a research report on Tuesday, September 16th. Wall Street Zen upgraded shares of Belite Bio from a "sell" rating to a "hold" rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $96.00.

Belite Bio Trading Down 4.2%

Shares of BLTE traded down $3.05 during mid-day trading on Wednesday, reaching $70.20. The company's stock had a trading volume of 71,038 shares, compared to its average volume of 42,799. Belite Bio has a 52 week low of $43.70 and a 52 week high of $86.53. The company's fifty day moving average price is $65.67 and its two-hundred day moving average price is $63.17. The stock has a market cap of $2.24 billion, a PE ratio of -45.29 and a beta of -1.50.

Institutional Investors Weigh In On Belite Bio

Hedge funds have recently bought and sold shares of the stock. GAMMA Investing LLC raised its position in Belite Bio by 43.3% during the first quarter. GAMMA Investing LLC now owns 1,849 shares of the company's stock valued at $122,000 after purchasing an additional 559 shares in the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Belite Bio in the 4th quarter worth about $155,000. EverSource Wealth Advisors LLC acquired a new stake in shares of Belite Bio in the 2nd quarter worth about $147,000. Marshall Wace LLP acquired a new stake in shares of Belite Bio in the 2nd quarter worth about $547,000. Finally, Bank of America Corp DE raised its holdings in shares of Belite Bio by 36.4% in the 4th quarter. Bank of America Corp DE now owns 18,342 shares of the company's stock worth $1,157,000 after acquiring an additional 4,891 shares during the last quarter. 0.53% of the stock is currently owned by institutional investors and hedge funds.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.